Category: RYBREVANT
-
RYBREVANT ® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
•
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT ® plus LAZCLUZE™ regimen compared to osimertinib monotherapy as first-line therapy Results from an interim analysis featured in late-breaker oral presentation at WCLC SAN DIEGO, Sept. 8, 2024 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced…